Floatz logo

Abemaciclib

Osteosarcoma, Recurrent, Refractory

Emory UniversitySmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

59 Active assets in the Osteosarcoma, Recurrent, Refractory cohort.

Asset / SponsorPhaseRating
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
(+)-VINCRISTINE
Milton S. Hershey Medical Center
Phase 2BB
Ipilimumab
Children's National Research Institute
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

Abemaciclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Hormone Receptor Positive TumorDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →